Herceptin Less-Frequent Dosing Is Preferred For Early-Stage Breast Cancer, NICE Says
U.K.’s NICE supports adoption of three-week interval dosing for trastuzumab for early-stage HER2-positive breast cancer.
U.K.’s NICE supports adoption of three-week interval dosing for trastuzumab for early-stage HER2-positive breast cancer.